The Frequency of Pd-L1 Marker Expression in Er Positive, Pr Positive, Her2 Negative Invasive Breast Carcinomas, and Its Correlation With Clinicopathological Factors Affecting Prognosis Publisher



Mohammadizadeh F ; Naraki T ; Vafaei M
Source: Advanced Biomedical Research Published:2025

Abstract

Background: The aim of this study was to investigate the expression of the PD‑L1 marker in ER‑positive, PR‑positive, and HER2‑negativebreast carcinoma and examine its correlation with clinicopathological factors that affect prognosis in these patients.Materials and Methods: This cross‑sectional descriptive–analytical study was conducted on paraffin‑embedded tissue blocks from 50 invasivebreast carcinoma patients. PD‑L1 immunohistochemical staining was performed, and samples were examined to assess the membranousstaining of tumor cells with the PD‑L1 marker. ER, PR, and HER2 results were obtained from the pathology reports. The tumor proliferativeindex was divided into two groups: low proliferative index (<14%) and high proliferative index (= or >14%), based on the percentage oftumor cell nuclei with positive staining.Results: PD‑L1 expression was negative in 44 (88%) and positive in 6 samples (12%). There was no significant difference in the mean age,tumor grade, and tumor proliferative index between the two groups (P value > 0.05). All positive PD‑L1 samples belonged to the IDC tumorsubtype with a mean tumor size of 6.33 ± 6.41 cm. In the negative PD‑L1 group, 88.6% were IDC, 4.5% were ILC, and 6.8% were mixedtumor subtypes, with a mean tumor size of 2.79 ± 1.54 cm. Tumor subtype, tumor size, and axillary lymph node status showed no significantdifference between the two groups (P value > 0.05).Conclusion: According to the results of this study, there is no relationship between the PD‑L1 expression and well‑known clinicopathologicalprognostic factors in ER‑positive, PR‑positive, and HER2‑negative invasive breast carcinomas. © 2025 Advanced Biomedical Research.